Biopharma

Bristol Myers' cost savings drive claims another 223 jobs in NJ

Bristol Myers' cost savings drive claims another 223 jo...

Mar 3, 2025 0

Beginning in late May, BMS will lay off 223 workers in Lawrenceville, New Jersey...

Human medicines European public assessment report (EPAR): Xoterna Breezhaler, indacaterol,glycopyrronium bromide, Date of authorisation: 18/09/2013, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Xoterna Breezhaler, in...

Sanofi bounces midstage ILT2 asset back to Biond Biologics after $125M bet

Sanofi bounces midstage ILT2 asset back to Biond Biolog...

Mar 3, 2025 0

The company is handing back the tumor candidate it snapped up in 2021 after init...

Rural-urban divide in cervical cancer means more cases and deaths

Rural-urban divide in cervical cancer means more cases ...

Mar 3, 2025 0

After a long decline, cervical cancer rates are rising in rural counties, increa...

Neumora halts trial of depression drug, rethinks 2 others to apply lessons from phase 3 failure

Neumora halts trial of depression drug, rethinks 2 othe...

Mar 3, 2025 0

Neumora halted one trial of its depression drug navacaprant and paused another p...

Human medicines European public assessment report (EPAR): Tecartus, Brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Tecartus, Brexucabtage...

STAT+: Protagonist drug hits goals in pivotal study of rare blood cancer

STAT+: Protagonist drug hits goals in pivotal study of ...

Mar 3, 2025 0

An experimental medicine from Protagonist Therapeutics stabilized red blood cell...

Fierce Biotech Fundraising Tracker '25: Callio launches with $187M series A; Eikon's eye-catching $350M series D

Fierce Biotech Fundraising Tracker '25: Callio launches...

Mar 3, 2025 0

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

Human medicines European public assessment report (EPAR): Anagrelide Viatris (previously Anagrelide Mylan), anagrelide, Date of authorisation: 15/02/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Anagrelide Viatris (pr...

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, European Medicines Agency, Amsterdam, the Netherlands, from 1 April 2025, 09:00 (CEST) to 2 April 2025, 15:50 (CEST)

European Medicines Agency (EMA) Patients' and Consumers...

Mar 3, 2025 0

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare P...

Lexicon feels the pain as midphase non-opioid data underwhelm investors

Lexicon feels the pain as midphase non-opioid data unde...

Mar 3, 2025 0

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-op...

Human medicines European public assessment report (EPAR): Orserdu, elacestrant, Date of authorisation: 15/09/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Orserdu, elacestrant, ...

STAT+: Republicans’ new Medicaid arguments: They’re only cutting waste, fraud, and abuse

STAT+: Republicans’ new Medicaid arguments: They’re onl...

Mar 3, 2025 0

A conservative group's study claims there's a high level of improper payments in...

Human medicines European public assessment report (EPAR): EndolucinBeta, lutetium (177 Lu) chloride, Date of authorisation: 06/07/2016, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): EndolucinBeta, lutetiu...

Human medicines European public assessment report (EPAR): Obodence, denosumab, Date of authorisation: 12/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Obodence, denosumab, D...

From research to reality: how studying innovative HIV medicines in the “real world” helps HCPs and patients make the best decisions for treatment and prevention

From research to reality: how studying innovative HIV m...

Mar 3, 2025 0

Dr. Buzón discusses bridging science and reality, highlighting the vital role of...

STAT+: Pharmalittle: We’re reading about HHS reducing public comment, a Lilly obesity drug ad, and more

STAT+: Pharmalittle: We’re reading about HHS reducing p...

Mar 3, 2025 0

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation f...

STAT+: Turbulence at the FDA & bluebird Bio’s sale

STAT+: Turbulence at the FDA & bluebird Bio’s sale

Mar 3, 2025 0

Friday's biotech news includes Pfizer's shifting DEI focus and Eli Lilly's costl...

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Nepexto, etanercept, D...

Regulatory Procedure Management (RPM) for the Product L...

Mar 3, 2025 0

Regulatory Procedure Management (RPM) for the Product Lifecycle Management (PLM)...

An easier path for makers of seasonal flu vaccines

An easier path for makers of seasonal flu vaccines

Mar 3, 2025 0

The biotech news stories you need to read, brought to you by The Readout.

Q&A clinic on web-based electronic Application Form (eAF) functionalities for CAPs and non-CAPs variations, Online, European Medicines Agency, Amsterdam, the Netherlands, from 6 March 2025, 11:00 (CET) to 6 March 2025, 11:30 (CET)

Q&A clinic on web-based electronic Application Form (eA...

Mar 3, 2025 0

Q&A clinic on web-based electronic Application Form (eAF) functionalities for CA...

Frazier arms Callio with $187M series A to fly Hummingbird's HER2 dual payload ADC to clinic

Frazier arms Callio with $187M series A to fly Hummingb...

Mar 3, 2025 0

Frazier Life Sciences has launched Callio Therapeutics with $187 million in seri...

Human medicines European public assessment report (EPAR): Beyonttra, acoramidis, Date of authorisation: 10/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025 0

Human medicines European public assessment report (EPAR): Beyonttra, acoramidis,...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.